8 results about "Thermolabile" patented technology

To provide dsRNA molecules which are advantageous for inhibition of target gene expression while having reduced off-target gene silencing effects.SOLUTION: The present invention relates to double-stranded RNA (dsRNA) agent capable of inhibiting the expression of a target gene. The antisense strand of the dsRNA molecule comprises at least one thermally destabilizing nucleotide occurring at a seed region; the dsRNA comprises at least four 2'-fluoro modifications; and the sense strand of the dsRNA molecule comprises a ligand, where the ligand is an ASGPR ligand.SELECTED DRAWING: None

The abstract relates to the field of pharmacy, in particular, to a method for obtaining extracts from medicinal plants and can be used for the production of biologically active additives, cosmetics and medicines with antioxidant, rejuvenating and anti-inflammatory effects. The essence of the utility model is the development of a technology for obtaining a liquid extract rich in biologically active compounds by ultrasonic processing of Rosa platyacantha Schrenk leaf raw materials. The method includes the following steps: 1. Preparation of plant raw materials (grinding to 5 mm); 2. Preparation of extractant (50% ethyl alcohol); 3. Extraction of raw materials and extractant in a ratio of 1:10 (Elma Elmasonic Easy 30H); 4. Filtration of the resulting liquid extract; 5. Packaging and labeling of the finished product. Extraction is carried out at a temperature of 35°C and a frequency of 37 kHz for 30 minutes. The technical result of the proposed approach is the development of a resource-saving technology for obtaining a liquid extract from the leaves of Rosa platyacantha Schrenk, ensuring a reduction in extraction time, a low temperature regime while preserving thermolabile biologically active substances, and an expansion of the raw material base through the use of previously unused parts of the plant.

New compositions and methods are described herein operable for delivery of therapeutic agents while mitigating damage to healthy tissues. In one aspect, a conjugate comprises a linker joining a pharmaceutical component and a targeting ligand, wherein the linker is at least one of radiolabile, photolabile, thermolabile, chemically labile, magnetically labile, or acoustolabile for release of the targeting ligand and / or the pharmaceutical component from the conjugate.

The invention establishes a method for simultaneously detecting vibrio parahaemolyticus, staphylococcus aureus, listeria monocytogenes, salmonella, shigella, bacillus cereus and vibrio alginolyticus on the basis of multiple PCR (Polymerase Chain Reaction) combined with a gene chip technology. The method comprises the following steps: selecting a heat-labile hemolysin gene of vibrio parahaemolyticus, a heat-resistant nuclease gene of staphylococcus aureus, a coded hemolysin O gene hlyA of listeria monocytogenes, an invasive protein A gene of salmonella enteritidis and an invasive plasmid antigen H gene of Shigella to carry out quintuple PCR (Polymerase Chain Reaction) amplification; bacillus cereus non-hemolytic toxin genes and vibrio alginolyticus similar Rpos sigma factor genes are selected for double PCR, two groups of multiplex PCR amplification products are hybridized with specific probes on the chip at the same time, and seven food-borne pathogenic bacteria can be detected at the same time. The method for detecting pathogenic bacteria by using the gene chip is high in specificity, high in sensitivity and strong in reliability.

This disclosure generally relates to gas-phase methods to simultaneously purify and decarboxylate cannabinoids in about two seconds, which are about 100-10,000 times more efficient than conventional purification and decarboxylation strategies. The methods also recover thermolabile cannabinoids such as cannabigerol at significantly higher yields than conventional methods.

A method and system for the thermal stabilization of pharmaceutical formulations containing proteins and monoclonal antibodies is disclosed. The disclosed method of rapid room temperature aerosol dehydration (RTAD) provides a scalable system for the continuous dehydration of liquid pharmaceutical formulations and biopharmaceutical formulations that provides thermal stabilization of biopharmaceuticals by converting the liquid pharmaceuticals into a powder form, enabling them to be transported, stored and handled at room temperature. The disclosed method can generate a spray / aerosol with droplet sizes that are 100 times smaller (0.2-20 μm) than existing spray drying techniques and dehydrates without the application of heat, mitigating the risk of damage to heat labile biologies and providing a significant reduction in energy requirements. The technology has demonstrated that the system is superior to conventional spray drying and freeze drying in terms of energy consumption, bioactivity, scalability, powder solubility, reduction of protein aggregation, particle size and size uniformity, and the high quality of the resulting inhalable and reconstitutable biopharmaceuticals.

Disclosed are a method and system for thermal stabilization of pharmaceutical formulations containing enveloped and nonenveloped viruses. The disclosed method of Rapid Room Temperature Aerosol Dehydration (RTAD) provides a scalable system for continuous dehydration of liquid pharmaceutical and biopharmaceutical formulations that provides thermal stabilization of biological drugs by converting liquid drugs into powder form, enabling their transportation, storage and handling at room temperature. The disclosed process can generate sprays / aerosols with droplets that are 100x smaller (0.2-20 μm) than existing spray drying technologies and perform dehydration, without applying heat, which mitigates the risk of damage of thermolabile biologicals and provides a significant reduction in energy requirements. The technology has demonstrated superiority of the system over traditional spray drying and freeze drying with respect to energy consumption, biological activity, scalability, powder solubility, particle size and size uniformity, and high-quality of produced inhalable and reconstitutable biologic formulations.

The invention relates to the field of food. Disclosed herein is a method of making a non-animal protein food product or cultured meat food product, comprising: adding a heat labile glucoamylase protein formulation to an ingredient for making the food product, and processing the obtained glucoamylase protein formulation and ingredient composition into a non-animal protein food product or a cultured meat food product.